Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Brett Reynolds as its new Chief Financial Officer, effective immediately. Mr. Reynolds has over 25 years of experience in financial leadership roles, primarily in the life sciences industry, and succeeds Tim Heher, who recently retired from the Company.